|Heterogeneity of genomic evolution and mutational profiles in multiple myeloma|
N Bolli, H Avet-Loiseau, DC Wedge, P Van Loo, LB Alexandrov, ...
Nature communications 5 (1), 1-13, 2014
|A small molecule inhibitor of ubiquitin-specific protease-7 induces apoptosis in multiple myeloma cells and overcomes bortezomib resistance|
D Chauhan, Z Tian, B Nicholson, KGS Kumar, B Zhou, R Carrasco, ...
Cancer cell 22 (3), 345-358, 2012
|Anti-DKK1 mAb (BHQ880) as a potential therapeutic agent for multiple myeloma|
M Fulciniti, P Tassone, T Hideshima, S Vallet, P Nanjappa, SA Ettenberg, ...
Blood, The Journal of the American Society of Hematology 114 (2), 371-379, 2009
|Blockade of XBP1 splicing by inhibition of IRE1α is a promising therapeutic option in multiple myeloma|
N Mimura, M Fulciniti, G Gorgun, YT Tai, D Cirstea, L Santo, Y Hu, ...
Blood, The Journal of the American Society of Hematology 119 (24), 5772-5781, 2012
|HLA class I, NKG2D, and natural cytotoxicity receptors regulate multiple myeloma cell recognition by natural killer cells|
E Carbone, P Neri, M Mesuraca, MT Fulciniti, T Otsuki, D Pende, V Groh, ...
Blood 105 (1), 251-258, 2005
|Elevated IL-17 produced by Th17 cells promotes myeloma cell growth and inhibits immune function in multiple myeloma|
RH Prabhala, D Pelluru, M Fulciniti, HK Prabhala, P Nanjappa, W Song, ...
Blood, The Journal of the American Society of Hematology 115 (26), 5385-5392, 2010
|Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma|
BA Walker, K Mavrommatis, CP Wardell, TC Ashby, M Bauer, FE Davies, ...
Blood, The Journal of the American Society of Hematology 132 (6), 587-597, 2018
|Activin A promotes multiple myeloma-induced osteolysis and is a promising target for myeloma bone disease|
S Vallet, S Mukherjee, N Vaghela, T Hideshima, M Fulciniti, S Pozzi, ...
Proceedings of the National Academy of Sciences 107 (11), 5124-5129, 2010
|A high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysis|
BA Walker, K Mavrommatis, CP Wardell, TC Ashby, M Bauer, F Davies, ...
Leukemia 33 (1), 159-170, 2019
|Pharmacologic targeting of a stem/progenitor population in vivo is associated with enhanced bone regeneration in mice|
S Mukherjee, N Raje, JA Schoonmaker, JC Liu, T Hideshima, MN Wein, ...
The Journal of clinical investigation 118 (2), 491-504, 2008
|PI3K/p110δ is a novel therapeutic target in multiple myeloma|
H Ikeda, T Hideshima, M Fulciniti, G Perrone, N Miura, H Yasui, Y Okawa, ...
Blood, The Journal of the American Society of Hematology 116 (9), 1460-1468, 2010
|Targeted disruption of the BCL9/β-catenin complex inhibits oncogenic Wnt signaling|
K Takada, D Zhu, GH Bird, K Sukhdeo, JJ Zhao, M Mani, M Lemieux, ...
Science translational medicine 4 (148), 148ra117-148ra117, 2012
|The monoclonal antibody nBT062 conjugated to cytotoxic Maytansinoids has selective cytotoxicity against CD138-positive multiple myeloma cells in vitro and in vivo|
H Ikeda, T Hideshima, M Fulciniti, RJ Lutz, H Yasui, Y Okawa, T Kiziltepe, ...
Clinical Cancer Research 15 (12), 4028-4037, 2009
|Bruton tyrosine kinase inhibition is a novel therapeutic strategy targeting tumor in the bone marrow microenvironment in multiple myeloma|
YT Tai, BY Chang, SY Kong, M Fulciniti, G Yang, Y Calle, Y Hu, J Lin, ...
Blood, The Journal of the American Society of Hematology 120 (9), 1877-1887, 2012
|Specific killing of multiple myeloma cells by (-)-epigallocatechin-3-gallate extracted from green tea: biologic activity and therapeutic implications|
MA Shammas, P Neri, H Koley, RB Batchu, RC Bertheau, V Munshi, ...
Blood 108 (8), 2804-2810, 2006
|Targeting mitochondrial factor Smac/DIABLO as therapy for multiple myeloma (MM)|
D Chauhan, P Neri, M Velankar, K Podar, T Hideshima, M Fulciniti, ...
Blood 109 (3), 1220-1227, 2007
|miR-29b sensitizes multiple myeloma cells to bortezomib-induced apoptosis through the activation of a feedback loop with the transcription factor Sp1|
N Amodio, MT Di Martino, U Foresta, E Leone, M Lionetti, M Leotta, ...
Cell death & disease 3 (11), e436-e436, 2012
|Genomic landscape and chronological reconstruction of driver events in multiple myeloma|
F Maura, N Bolli, N Angelopoulos, KJ Dawson, D Leongamornlert, ...
Nature communications 10 (1), 1-12, 2019
|Drugging the lncRNA MALAT1 via LNA gapmeR ASO inhibits gene expression of proteasome subunits and triggers anti-multiple myeloma activity|
N Amodio, MA Stamato, G Juli, E Morelli, M Fulciniti, M Manzoni, E Taiana, ...
Leukemia 32 (9), 1948-1957, 2018
|Neutralizing B-Cell–Activating Factor Antibody Improves Survival and Inhibits Osteoclastogenesis in a Severe Combined Immunodeficient Human Multiple Myeloma Model|
P Neri, S Kumar, MT Fulciniti, S Vallet, S Chhetri, S Mukherjee, YT Tai, ...
Clinical Cancer Research 13 (19), 5903-5909, 2007